It is curious that most physicians believe that their practices are not influenced by direct-to-physician marketing, yet the pharmaceutical industry continues to spend enormous sums of money – billions of dollars in the US annually – on this activity (1). Clearly, the pharmaceutical companies are seeing a return on their investment in physician marketing (2), though it is in their best interest, and that of physicians, to downplay its impact…
Filed under: Message From the Editor | Tagged: conflict of interest, pharmaceutical marketing, direct-to-physician marketing, financial disclosure, sunshine bill, prescribing data, Prescribing Data Restriction Program, AMA physician masterfile, research grants, Avonex, Betaseron, Copaxone, Rebif, industry-sponsored research, bias | Leave a Comment »
